rs56239539
Variant summary
Our verdict is Benign. Variant got -7 ACMG points: 2P and 9B. PM2BP4_StrongBP6BS1
The NM_133642.5(LARGE1):c.391G>A(p.Val131Ile) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000549 in 1,614,114 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. 13/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_133642.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -7 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
LARGE1 | NM_133642.5 | c.391G>A | p.Val131Ile | missense_variant | 3/15 | ENST00000397394.8 | NP_598397.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
LARGE1 | ENST00000397394.8 | c.391G>A | p.Val131Ile | missense_variant | 3/15 | 5 | NM_133642.5 | ENSP00000380549.2 |
Frequencies
GnomAD3 genomes AF: 0.000328 AC: 50AN: 152216Hom.: 1 Cov.: 32
GnomAD3 exomes AF: 0.000576 AC: 143AN: 248112Hom.: 1 AF XY: 0.000699 AC XY: 94AN XY: 134538
GnomAD4 exome AF: 0.000572 AC: 836AN: 1461780Hom.: 0 Cov.: 32 AF XY: 0.000627 AC XY: 456AN XY: 727208
GnomAD4 genome AF: 0.000328 AC: 50AN: 152334Hom.: 1 Cov.: 32 AF XY: 0.000242 AC XY: 18AN XY: 74496
ClinVar
Submissions by phenotype
not provided Uncertain:3Benign:1
Uncertain significance, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Jan 15, 2016 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Apr 17, 2019 | - - |
Likely benign, criteria provided, single submitter | clinical testing | GeneDx | Jan 06, 2020 | This variant is associated with the following publications: (PMID: 28454995) - |
Uncertain significance, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Feb 16, 2022 | - - |
not specified Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Athena Diagnostics | Feb 03, 2017 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Oct 12, 2023 | Variant summary: LARGE1 c.391G>A (p.Val131Ile) results in a conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.00063 in 254490 control chromosomes in the gnomAD database, including 1 homozygotes. c.391G>A has been reported in the literature in an individual affected with Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A who carried a second variant of uncertain significance in the compound heterozygous state. These data do not allow any conclusion about variant significance. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Seven submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. Multiple submitters reported the variant with conflicting assessments including four VUS and three likely benign classifications. Based on the evidence outlined above, the variant was classified as uncertain significance. - |
Inborn genetic diseases Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 06, 2021 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Muscular dystrophy-dystroglycanopathy type B6 Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 29, 2024 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at